EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations

Chio Yokose iD, Natalie McCormick iD, Na Lu, Bohang Jiang, Kiara Tan, Saiajay Chigurupati, Sharan K Rai, Greg Challener, J Antonio Aviña-Zubieta iD, Edoardo Cipolletta iD, Abhishek Abhishek iD, Angelo Gaffo iD und 3 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43259 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Chio Yokose und 14 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital and Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Gout, Colchicine, Anti-Inflammatory Agents, Non-Steroidal, Gout Suppressants. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAMS NIH HHS, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Among patients with gout, nonsteroidal anti‐inflammatory drugs (NSAIDs) are commonly used despite scarce safety data in this specific population. Therefore, we quantified the comparative cardiovascular safety of NSAIDs versus colchicine among patients with gout starting allopurinol.

Methods

We conducted a sequential, propensity score–matched, new‐user comparative effectiveness study using the target trial emulation framework to compare the risk of major adverse cardiovascular events (MACE; composite of myocardial infarction [MI], stroke, or cardiovascular death) among patients with gout started on allopurinol who were prescribed NSAIDs or colchicine for gout flare prophylaxis. A sensitivity analysis employed inverse probability of treatment weighting (IPTW). Secondarily, we examined the risk of MACE with colchicine or NSAIDs versus no prophylaxis.

Results

Among 18,120 propensity score–matched adults with gout starting allopurinol with NSAIDs or colchicine (83.5% male, mean age 60.9 years), the incidence of MACE and cardiovascular death were higher among NSAID users compared to colchicine users, with rate differences of 38.8 (95% confidence interval [CI] 15.4–62.2) and 10.9 (95% CI 0.7–21.1) per 1,000 person‐years, respectively, and hazard ratios (HRs) of 1.56 (95% CI 1.11–2.17) and 2.50 (95% CI 1.14–5.26), respectively. Results were similar when IPTW was applied. Compared to no prophylaxis, NSAID use was associated with a higher risk of MACE and MI, with HRs of 1.50 (95% CI 1.17–1.91) and 1.93 (95% CI 1.35–2.75), respectively.

Conclusion

In these target trial emulations of patients with gout starting allopurinol, NSAID prophylaxis was associated with a higher risk of MACE than colchicine or no prophylaxis, suggesting the avoidance of NSAID for gout flare prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutColchicineAnti-Inflammatory Agents, Non-SteroidalGout SuppressantsAllopurinolCardiovascular DiseasesHumansMaleMiddle AgedFemaleAgedMyocardial InfarctionUric AcidPropensity ScoreStroke

Substanzen

ColchicineAnti-Inflammatory Agents, Non-SteroidalGout SuppressantsAllopurinolUric Acid

Autor:innen und Institutionen

  • Massachusetts General Hospital and Harvard Medical School, Boston.
  • Massachusetts General Hospital and Harvard Medical School, Boston, and Arthritis Research Canada, Vancouver, British Columbia, Canada.
  • Arthritis Research Canada, Vancouver, British Columbia, Canada.
  • Arthritis Research Canada and Division of Rheumatology, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom, and Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
  • Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom.

ORCID-Profile: Chio Yokose, Natalie McCormick, J Antonio Aviña-Zubieta, Edoardo Cipolletta, Abhishek Abhishek, Angelo Gaffo, Yuqing Zhang

Förderung

  • NIH HHS
  • NIAMS NIH HHS
  • CIHR
  • National Institutes of Health
  • Canadian Institutes of Health Research

Zitieren

APA

Yokose, C., McCormick, N., Lu, N., Jiang, B., Tan, K., Chigurupati, S., Rai, S. K., Challener, G., Aviña-Zubieta, J. A., Cipolletta, E., Abhishek, A., Gaffo, A., Januzzi, J. L., Zhang, Y., & Choi, H. K. (2025). Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations. Arthritis & Rheumatology. https://doi.org/10.1002/art.43259

Vancouver

Yokose C, McCormick N, Lu N, Jiang B, Tan K, Chigurupati S, et al. Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations. Arthritis & Rheumatology. 2025. doi:10.1002/art.43259

BibTeX
@article{Yokose2025,
  author = {Yokose, Chio and McCormick, Natalie and Lu, Na and Jiang, Bohang and Tan, Kiara and Chigurupati, Saiajay and Rai, Sharan K and Challener, Greg and Aviña-Zubieta, J Antonio and Cipolletta, Edoardo and Abhishek, Abhishek and Gaffo, Angelo and Januzzi, James L and Zhang, Yuqing and Choi, Hyon K},
  title = {Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43259}
}
Kostenlos starten →